Navigation Links
Amerigen Pharmaceuticals and VIWA Pharmaceutical Company Today Jointly Announce the Signing of a Memorandum of Understanding (MOU) Setting Out Their Intention to Establish a Joint Venture to Develop and Register a Range of Branded Generic Medicines
Date:1/11/2012

EAST BRUNSWICK, N.J. and HANGZHOU, China, Jan. 11, 2012 /PRNewswire/ -- Amerigen Pharmaceuticals Limited and VIWA Pharmaceutical Company Limited today jointly announce the signing of a memorandum of understanding (MOU) setting out their intention to establish a joint venture to develop and register a range of branded generic medicines for sale in China. It is anticipated that the products, once approved, would be manufactured at Amerigen's SFDA and US FDA approved finished dose plant in Suzhou, China, with marketing and sales undertaken either by a Chinese affiliate of VIWA or a third party. Jonathan Embleton, Amerigen's Chief Business Officer commented, "We look forward to working with VIWA to bring some first time and technically sophisticated generic products to Chinese patients at more affordable prices, without compromising on quality."

Jack H. Ye, VIWA's managing director, added, "Combining Amerigen's development capabilities, manufacturing assets and access to products from Western markets with VIWA's access to API's and regulatory expertise in China should enable the joint venture to rapidly build up its product portfolio. This in turn will help accelerate VIWA's strategic thrust into the commercialization of finished pharmaceutical products in China."

John Lowry, Amerigen's President & CEO added, "The formation of this joint venture marks a first step by Amerigen to bring high quality and locally manufactured branded generic products to the Chinese market and, in the process, establish an Amerigen brand in China. We anticipate that additional collaborations will be established to further this strategy."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in East Brunswick, NJ, USA. The group's Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA and the Chinese SFDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.

About VIWA
VIWA Pharmaceutical Company Limited is a member of the VIWA group of companies and is focused on the development, registration and commercialization of finished pharmaceutical products within China and for export to other markets. The VIWA group of companies also includes the Hangzhou VIWA Company Limited, a leading provider of active pharmaceutical ingredients, fine chemicals and intermediates to the global pharmaceutical, agrochemical and animal health industries.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products
2. Amerigen Pharmaceuticals and Stason Pharmaceuticals Enter Into Collaboration Agreement for Development of Generic Oral Oncology Products
3. Amerigen Pharmaceuticals and the Shanghai Fosun Omni Pharmaceutical Company Enter Into Collaboration Agreement for the Development of Generic Oral Controlled Release Products
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 True Health Diagnostics ... leading-edge laboratory services and management expertise to hospital ... , allowing more doctors and patients to benefit ... solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... systems, under pressure to contain costs, have struggled ...
(Date:12/8/2016)... Information products and services provider Elsevier ... Scopus , the world,s largest abstract and citation database of peer-reviewed ... journals from over 5,000 publishers. The new set of metrics will ... and when to adjust a journal,s editorial strategy. ... , , ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... Vida ... an $18M Series B led by Canvas Ventures . Other investors include Nokia ... scale its mobile platform to serve more consumers who are managing chronic conditions ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... planning services from offices headquartered in Jefferson County, is announcing the launch of ... in Birmingham. , The number of homeless women and children in Birmingham has ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Compretta Insurance Agency, a family owned ... and around the Hancock County area, is announcing the launch of a charity effort ... The Hancock County Food Pantry has worked for more than 30 years to meet ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated ... it is one of the early adopters completing EU-U.S. Privacy Shield Certification from the ... provide companies on both sides of the Atlantic with a mechanism to comply with ...
(Date:12/7/2016)... ... ... Kenall Manufacturing, a leader in sealed healthcare lighting for more than 30 years, ... LED luminaire that meets the needs of everyone in the patient room by delivering ... A 2’ x 4’ model features four modes: reading, ambient, standard and high output ...
Breaking Medicine News(10 mins):